Item 1.01 Entry into a Material Definitive Agreement.
Registration Rights Agreement
On March 4, 2025, Aadi Bioscience, Inc. (the “Company”) consummated its previously announced private placement (the “PIPE Financing”). At the closing of the PIPE Financing, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the purchasers in the PIPE Financing. Pursuant to the Registration Rights Agreement, the Company will prepare and file a resale registration statement with the Securities and Exchange Commission (“SEC”) on or prior to the later of (i) thirty (30) days following the closing of the PIPE Financing and (ii) five (5) business days following the filing of the Company’s audited financial statements for the year ended December 31, 2024. The Company will use its commercially reasonable efforts to cause this registration statement to be declared effective by the SEC within 60 calendar days of the closing of the PIPE Financing (or within 90 calendar days if the SEC reviews the registration statement), subject to acceleration under certain circumstances.
The Company also agreed, among other things, to indemnify each participating holder, their officers, directors, members, employees, and agents, successors and assigns, and each other person, if any, who controls such participating holder within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), under the registration statement from certain losses, claims, damages, liabilities and expenses incident to the Company’s obligations under the Registration Rights Agreement.
The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated by reference into this Item 1.01.
Amendment and Restatement of the Company’s 2021 Equity Incentive Plan
As described in Item 5.07 below, at the Special Meeting, the Company’s stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) to (i) increase the number of shares available for future grant under the 2021 Plan from 2,000,284 shares to 8,300,284 shares and (ii) increase the 2021 Plan’s default annual automatic share reserve increase occurring on January 1 of each year from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5%. Upon stockholder approval, such amendment and restatement of the 2021 Plan became effective.
A copy of the amended and restated 2021 Plan that was approved by the Company’s stockholders was included as Annex H to the Company’s definitive proxy statement for the Special Meeting, filed with the SEC on January 31, 2025 (the “Special Meeting Proxy Statement”), and is available at the SEC’s website at www.sec.gov. The terms and conditions of the amended and restated 2021 Plan are described in detail in the Special Meeting Proxy Statement.
The foregoing description of the amended and restated 2021 Plan does not purport to be complete and is qualified in its entirety by reference to the amended and restated 2021 Plan, a copy of which is filed as Exhibit 10.2 hereto and incorporated by reference herein.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held a special meeting of stockholders on February 28, 2025 (the “Special Meeting”). At the Special Meeting, 20,105,684 shares of common stock of the Company, representing approximately 81.41% of the voting power of all issued and outstanding shares of common stock of the Company as of January 30, 2025, the record date for the Special Meeting, and constituting a quorum for the transaction of business, were present in person or by proxy and considered and voted on the following proposals, each of which is described in more detail in the Special Meeting Proxy Statement:
|
(1) |
Approval of the sale by the Company to KAKEN INVESTMENTS INC. of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. and thereby all or substantially all of the Company’s assets related to its FYARRO Business, pursuant to the terms of the Stock Purchase Agreement, dated as of December 19, 2024, which may be deemed to be a sale of substantially all of the Company’s assets under Section 271 of the Delaware General Corporation Law and to approve the Stock Purchase Agreement (the “Divestiture Proposal”); |